An Open-label, Randomized, Single-center, 4-way Crossover, Single Dose Bioequivalence Study Comparing Omeprazole 20 and 40-mg Aqueous Solvent Based Capsules Manufactured by AstraZeneca With Omeprazole 20 and 40-mg Organic-solvent Based Capsules Manufactured by Merck

Trial Profile

An Open-label, Randomized, Single-center, 4-way Crossover, Single Dose Bioequivalence Study Comparing Omeprazole 20 and 40-mg Aqueous Solvent Based Capsules Manufactured by AstraZeneca With Omeprazole 20 and 40-mg Organic-solvent Based Capsules Manufactured by Merck

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2013

At a glance

  • Drugs Omeprazole (Primary)
  • Indications Duodenal ulcer; Dyspepsia; Gastritis; Gastro-oesophageal reflux; Peptic ulcer; Zollinger-Ellison syndrome
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 21 Nov 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 09 Sep 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top